Media Pack
News

Current Edition

JCS Volume 15 Issue 3
 
Regional News

Another Samsung Bioepis? Biocon, Viatris mull merging biosimilar businesses

Samsung Bioepis represents the marriage of an Asian company and a Western drugmaker with a focus on biosimilars. Now, two other players are reportedly considering a s...
13 December 2021 Regional News Biocon | biosimilar
Continue Reading →
Regional News

China’s new NRDL; Biocon-Viatris biosimilar merger?; Avistone’s $200M series A

China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris ...
13 December 2021 Regional News antibody drugs | ASLAN Pharmaceuticals
Continue Reading →
Regional News

Alvotech, battling AbbVie over its Humira biosim, raises $450M and tees up Nasdaq debut

Alvotech, the biosim specialist locked in a legal battle over AbbVie's sales Goliath Humira, is revving up for its debut on the Nasdaq. The Icelandic company is join...
8 December 2021 Regional News AbbVie | Alvotech
Continue Reading →
Regional News

Amgen’s Otezla, Repatha and biosimilars put on notice, with challenging years ahead

Some of Amgen’s key businesses are drawing concerns as competition looms. Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry watche...
24 November 2021 Regional News Aimovig | Amgen Repatha
Continue Reading →
Regional News

Viatris launched two versions of its interchangeable insulin biosimilar. Why?

It's official: Biocon and Viatris have launched their historic interchangeable insulin biosimilar, Semglee. The drug, which references Sanofi's blockbuster diabetes m...
17 November 2021 Regional News Biocon | biosimilar
Continue Reading →
news

Pegfilgrastim Biosimilar Matches Reference Product

Sandoz's biosimilar of Neulasta, or pegfilgrastim, matched the reference product in a clinical trial, according to the company. Researchers found equivalence in pharm...
20 December 2017 news biosimilar | cancer
Continue Reading →
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2023, All Rights Reserved – Powered by Teksyte